At Novartis, we’re committed to unraveling the inner workings of cancer. We’re developing new therapies for a range of common and rare cancers, investing in diverse technology platforms and experimenting with combination approaches.

Reimagining medicine in cancer

We have the passion and the people to help transform lives as we pursue treatments for patients.

Our disease areas

At Novartis, we push the limits of science to develop innovative therapies. These therapies have the potential to be new foundations for cancer care in areas with great unmet need.

Doctor and patient discussing diagnosis

Breast cancer

Novartis aims to tackle breast cancer with bold science, collaboration, and a passion for transforming patient care. We take a bold approach to our research by including patient populations who are often neglected in clinical trials, identifying new pathways or mutations that may play a role in disease progression, and developing therapies to help extend and improve the lives of patients.

Elder woman holding hand of a patient

Lung cancer

Lung cancer is one of the most common cancers worldwide, accounting for more than 2 million new cases diagnosed each year. Novartis is committed to helping the lung cancer community by advancing the science to drive new treatments for lung cancer.

Doctor greeting a patient

Prostate cancer

We are harnessing the innovation of our world-class scientists, strategic partnerships, and one of the industry’s most competitive pipelines to explore the potential of our targeted therapies to address unmet needs in prostate cancer. Our goal is to reduce the global disease burden, extend the lives of patients with prostate cancer, and elevate current standards of care.

Doctor testing blood pressure


From targeted therapies, to precision cell and gene therapy and immunotherapy – we have been pioneers in hematology, staying on the cutting edge in order to tackle blood cancers and serious blood disorders. Our research continues in new and different ways to harness the power of immunotherapy and potentially benefit a broader patient population than ever before. We are changing the hematological paradigm, transforming what it means to live with blood cancer or a serious blood disorder.